301281 科源制药
交易中 03-30 10:25:42
资讯
新帖
简况
股市必读：科源制药（301281）3月26日收盘跌10.15%，主力净流出1995.85万元
证券之星 · 03-27
股市必读：科源制药（301281）3月26日收盘跌10.15%，主力净流出1995.85万元
股市必读：科源制药（301281）3月23日收盘跌10.32%，主力净流出284.85万元
证券之星 · 03-24
股市必读：科源制药（301281）3月23日收盘跌10.32%，主力净流出284.85万元
科源制药（301281）披露控股股东部分股份解除质押及再质押公告，3月16日股价上涨1.69%
证券之星 · 03-16
科源制药（301281）披露控股股东部分股份解除质押及再质押公告，3月16日股价上涨1.69%
科源制药股东拟减持不超过3%股份，减持计划为期三个月
美股速递 · 03-16
科源制药股东拟减持不超过3%股份，减持计划为期三个月
科源制药最新公告：股东济南鼎佑拟减持不超3.00%股份
证券之星 · 03-16
科源制药最新公告：股东济南鼎佑拟减持不超3.00%股份
科源制药（301281）披露全资子公司银行账户部分金额解除冻结的公告，3月13日股价上涨3.46%
证券之星 · 03-13
科源制药（301281）披露全资子公司银行账户部分金额解除冻结的公告，3月13日股价上涨3.46%
科源制药业绩“变脸”再陷困局：诉讼赔偿、战略摇摆与资金链隐忧并存
新浪证券 · 03-06
科源制药业绩“变脸”再陷困局：诉讼赔偿、战略摇摆与资金链隐忧并存
科源制药最新公告：预计2025年净利润同比减少70%-80%
证券之星 · 02-24
科源制药最新公告：预计2025年净利润同比减少70%-80%
2月24日科源制药发布公告，股东减持28.27万股
证券之星 · 02-24
2月24日科源制药发布公告，股东减持28.27万股
股市必读：科源制药（301281）预计2025年全年归属净利润盈利2720.19万元至3929.16万元
证券之星 · 02-02
股市必读：科源制药（301281）预计2025年全年归属净利润盈利2720.19万元至3929.16万元
科源制药（301281）披露2025年度业绩预告，1月30日股价下跌2.24%
证券之星 · 01-30
科源制药（301281）披露2025年度业绩预告，1月30日股价下跌2.24%
科源制药（301281）股东力诺投资控股集团有限公司质押150万股，占总股本1.39%
证券之星 · 01-30
科源制药（301281）股东力诺投资控股集团有限公司质押150万股，占总股本1.39%
科源制药（301281）披露2025年限制性股票激励计划议案获股东会通过，1月19日股价上涨2.12%
证券之星 · 01-19
科源制药（301281）披露2025年限制性股票激励计划议案获股东会通过，1月19日股价上涨2.12%
科源制药（301281）披露召开2026年第一次临时股东会提示性公告，1月14日股价上涨1.44%
证券之星 · 01-14
科源制药（301281）披露召开2026年第一次临时股东会提示性公告，1月14日股价上涨1.44%
科源制药：注射剂智能制造项目正稳步推进
证券之星 · 01-14
科源制药：注射剂智能制造项目正稳步推进
科源制药（301281）披露公司2025年限制性股票激励计划内幕信息知情人买卖公司股票情况的自查报告，1月13日股价上涨1.56%
证券之星 · 01-13
科源制药（301281）披露公司2025年限制性股票激励计划内幕信息知情人买卖公司股票情况的自查报告，1月13日股价上涨1.56%
每周股票复盘：科源制药（301281）推300万股限制性股票激励计划
证券之星 · 01-03
每周股票复盘：科源制药（301281）推300万股限制性股票激励计划
科源制药(301281.SZ)拟推2025年限制性股票激励计划
智通财经 · 2025-12-29
科源制药(301281.SZ)拟推2025年限制性股票激励计划
科源制药：在海南设有子公司林恒药业
证券之星 · 2025-12-10
科源制药：在海南设有子公司林恒药业
科源制药：三高和心血管原料药均有布局
证券之星 · 2025-12-09
科源制药：三高和心血管原料药均有布局
加载更多
公司概况
公司名称：
山东科源制药股份有限公司
所属行业：
医药制造业
上市日期：
2023-04-04
主营业务：
山东科源制药股份有限公司的主营业务是化学原料药及其制剂产品的研发、生产和销售。公司的主要产品是化学原料药、化学药品制剂、中间体。
发行价格：
44.18
{"stockData":{"symbol":"301281","market":"SZ","secType":"STK","nameCN":"科源制药","latestPrice":36.16,"timestamp":1774837542000,"preClose":39.2,"halted":0,"volume":3549200,"delay":0,"changeRate":-0.0776,"floatShares":68852000,"shares":108000000,"eps":0.4824,"marketStatus":"交易中","change":-3.04,"latestTime":"03-30 10:25:42","open":38.18,"high":38.76,"low":36.13,"amount":132000000,"amplitude":0.0671,"askPrice":36.16,"askSize":19,"bidPrice":36.15,"bidSize":62,"shortable":0,"etf":0,"ttmEps":0.4824,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1774841400000},"marketStatusCode":2,"adr":0,"adjPreClose":39.2,"symbolType":"stock","openAndCloseTimeList":[[1774834200000,1774841400000],[1774846800000,1774854000000]],"highLimit":43.12,"lowLimit":35.28,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":108290000,"isCdr":false,"pbRate":3.1,"roa":"--","peRate":74.958541,"roe":"2.3%","epsLYR":0.56,"committee":0.055351,"marketValue":3916000000,"turnoverRate":0.0515,"status":1,"floatMarketCap":2490000000},"requestUrl":"/m/hq/s/301281","defaultTab":"news","newsList":[{"id":"2622860304","title":"股市必读：科源制药（301281）3月26日收盘跌10.15%，主力净流出1995.85万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2622860304","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622860304?lang=zh_cn&edition=full","pubTime":"2026-03-27 01:12","pubTimestamp":1774545132,"startTime":"0","endTime":"0","summary":"截至2026年3月26日收盘，科源制药报收于41.7元，下跌10.15%，换手率9.41%，成交量6.48万手，成交额2.81亿元。交易信息汇总3月26日科源制药收盘报41.7元，跌10.15%，当日成交648.21万元。该股近5个交易日中有2日跌幅超5%。前10个交易日资金流向显示，主力资金累计净流出428.66万元，股价累计下跌13%；融资余额累计减少1765.98万元，融券余量累计增加0股。资金流向3月26日主力资金净流出1995.85万元；游资资金净流出1129.27万元；散户资金净流入3125.13万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032700002810.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301281"],"gpt_icon":0},{"id":"2621081721","title":"股市必读：科源制药（301281）3月23日收盘跌10.32%，主力净流出284.85万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2621081721","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621081721?lang=zh_cn&edition=full","pubTime":"2026-03-24 04:03","pubTimestamp":1774296196,"startTime":"0","endTime":"0","summary":"截至2026年3月23日收盘，科源制药报收于43.9元，下跌10.32%，换手率10.02%，成交量6.9万手，成交额3.19亿元。当日关注点来自交易信息汇总：科源制药3月23日收盘报43.9元，跌10.32%，主力资金净流出284.85万元，散户资金净流入1929.56万元。来自交易信息汇总：该股已连续2日下跌，前10个交易日主力资金累计净流入5236.93万元，股价累计上涨4.39%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032400004649.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301281","BK0239"],"gpt_icon":0},{"id":"2619619674","title":"科源制药（301281）披露控股股东部分股份解除质押及再质押公告，3月16日股价上涨1.69%","url":"https://stock-news.laohu8.com/highlight/detail?id=2619619674","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619619674?lang=zh_cn&edition=full","pubTime":"2026-03-16 22:20","pubTimestamp":1773670833,"startTime":"0","endTime":"0","summary":"截至2026年3月16日收盘，科源制药报收于50.45元，较前一交易日上涨1.69%，最新总市值为54.63亿元。该股当日开盘49.33元，最高50.95元，最低47.71元，成交额达1.91亿元，换手率为5.6%。公司于近日披露《关于控股股东部分股份解除质押及再质押的公告》。本次质押为力诺投资为力诺集团融资提供的质押担保，不涉及上市公司生产经营，不构成业绩补偿义务。截至公告日，力诺投资累计质押股份数量为29,340,000股，占其所持股份比例77.61%，占公司总股本比例27.09%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031600036672.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301281","BK0239"],"gpt_icon":0},{"id":"1177670331","title":"科源制药股东拟减持不超过3%股份，减持计划为期三个月","url":"https://stock-news.laohu8.com/highlight/detail?id=1177670331","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1177670331?lang=zh_cn&edition=full","pubTime":"2026-03-16 18:21","pubTimestamp":1773656468,"startTime":"0","endTime":"0","summary":"科源制药（301281）近日披露，公司一名股东计划在未来三个月内减持其所持有的公司股份，减持比例最高不超过公司总股本的3%。\n此次减持计划若按上限实施，可能对公司的股权结构产生一定影响。根据相关规定，股东减持需遵守信息披露要求，公司已及时对外公告该事项。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["301281","BK0239"],"gpt_icon":0},{"id":"2619256451","title":"科源制药最新公告：股东济南鼎佑拟减持不超3.00%股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2619256451","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619256451?lang=zh_cn&edition=full","pubTime":"2026-03-16 18:20","pubTimestamp":1773656424,"startTime":"0","endTime":"0","summary":"科源制药(301281.SZ)公告称，股东济南鼎佑健康产业投资合伙企业（有限合伙）计划以集中竞价及大宗交易方式减持公司股份不超过324.87万股（不超过公司总股本的3.00%）；减持原因为经营计划需求；集中竞价减持期间为公告披露之日起十五个交易日后的三个月内，大宗交易减持期间为公告披露之日起三个交易日后的三个月内。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031600028181.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301281","BK0239"],"gpt_icon":0},{"id":"2619158291","title":"科源制药（301281）披露全资子公司银行账户部分金额解除冻结的公告，3月13日股价上涨3.46%","url":"https://stock-news.laohu8.com/highlight/detail?id=2619158291","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619158291?lang=zh_cn&edition=full","pubTime":"2026-03-13 22:30","pubTimestamp":1773412244,"startTime":"0","endTime":"0","summary":"截至2026年3月13日收盘，科源制药报收于49.61元，较前一交易日上涨3.46%，最新总市值为53.72亿元。公司于近日披露《关于全资子公司银行账户部分金额解除冻结的公告》。公告显示，山东科源制药股份有限公司全资子公司山东力诺制药有限公司因与江苏赛邦药业有限公司合同纠纷，部分银行账户此前被冻结。2026年3月12日，力诺制药获悉其中一个银行账户部分金额已解除冻结，中国邮政储蓄银行账户解除冻结金额为40,760,000.00元，未解除冻结金额为16,240,000.00元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031300041753.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301281","161121","BK0239"],"gpt_icon":0},{"id":"2617064865","title":"科源制药业绩“变脸”再陷困局：诉讼赔偿、战略摇摆与资金链隐忧并存","url":"https://stock-news.laohu8.com/highlight/detail?id=2617064865","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617064865?lang=zh_cn&edition=full","pubTime":"2026-03-06 10:49","pubTimestamp":1772765340,"startTime":"0","endTime":"0","summary":"近日，科源制药因一则业绩预告修正公告引发市场广泛关注。表面诱因为一起诉讼赔偿，但背后折射出的，是企业连续三年业绩下滑、战略摇摆、资金链承压等多重困境。科源制药将此认定为资产负债表日后调整事项，计入2025年度营业外支出。 科源制药于2023年4月登陆A股，上市当年即出现净利润下滑15.6%的“变脸”行情。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/aigcy/2026-03-06/doc-inhpzkwr9249622.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["301281","BK0239"],"gpt_icon":0},{"id":"2613411717","title":"科源制药最新公告：预计2025年净利润同比减少70%-80%","url":"https://stock-news.laohu8.com/highlight/detail?id=2613411717","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613411717?lang=zh_cn&edition=full","pubTime":"2026-02-24 22:11","pubTimestamp":1771942285,"startTime":"0","endTime":"0","summary":"科源制药(301281.SZ)发布2025年度业绩预告修正公告，预计2025年归属于上市公司股东的净利润为1,208.97万元–1,813.45万元，比上年同期下降70%–80%。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022400043833.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301281"],"gpt_icon":0},{"id":"2613711105","title":"2月24日科源制药发布公告，股东减持28.27万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2613711105","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613711105?lang=zh_cn&edition=full","pubTime":"2026-02-24 21:01","pubTimestamp":1771938062,"startTime":"0","endTime":"0","summary":"证券之星消息，2月24日科源制药发布公告《科源制药:山东科源制药股份有限公司简式权益变动报告书》，其股东问泽鸿于2026年2月10日至2026年2月13日间合计减持28.27万股，占公司目前总股本的0.2611%，变动期间该股股价上涨11.37%，截止2月13日收盘报37.51元。股东增减持详情见下表：根据科源制药2025年三季报公布的十大股东详情如下：以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022400042539.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301281"],"gpt_icon":0},{"id":"2608889263","title":"股市必读：科源制药（301281）预计2025年全年归属净利润盈利2720.19万元至3929.16万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2608889263","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608889263?lang=zh_cn&edition=full","pubTime":"2026-02-02 03:52","pubTimestamp":1769975530,"startTime":"0","endTime":"0","summary":"业绩披露要点业绩预告科源制药发布业绩预告，预计2025年全年归属净利润盈利2,720.19万元至3,929.16万元；扣非后净利润预计盈利2,011.71万元至2,905.81万元。公司公告汇总2025年度业绩预告山东科源制药股份有限公司发布2025年度业绩预告，预计归属于上市公司股东的净利润为2,720.19万元至3,929.16万元，较上年同期的6,044.87万元下降35%-55%；扣除非经常性损益后的净利润预计为2,011.71万元至2,905.81万元，同比下降35%-55%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020200001801.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301281"],"gpt_icon":0},{"id":"2607428830","title":"科源制药（301281）披露2025年度业绩预告，1月30日股价下跌2.24%","url":"https://stock-news.laohu8.com/highlight/detail?id=2607428830","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607428830?lang=zh_cn&edition=full","pubTime":"2026-01-30 23:10","pubTimestamp":1769785818,"startTime":"0","endTime":"0","summary":"截至2026年1月30日收盘，科源制药报收于31.47元，较前一交易日下跌2.24%，最新总市值为34.08亿元。该股当日开盘32.54元，最高32.78元，最低30.92元，成交额达8870.3万元，换手率为4.08%。公司于2026年1月30日披露《2025年度业绩预告》。本次业绩预告未经审计，最终数据以2025年年度报告为准。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026013000048067.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301281"],"gpt_icon":0},{"id":"2607019475","title":"科源制药（301281）股东力诺投资控股集团有限公司质押150万股，占总股本1.39%","url":"https://stock-news.laohu8.com/highlight/detail?id=2607019475","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607019475?lang=zh_cn&edition=full","pubTime":"2026-01-30 18:29","pubTimestamp":1769768980,"startTime":"0","endTime":"0","summary":"证券之星消息，科源制药1月30日公开信息显示，股东力诺投资控股集团有限公司向中国邮政储蓄银行股份有限公司济南市分行合计质押150.0万股，占总股本1.39%。质押详情见下表：截止本公告日，股东力诺投资控股集团有限公司已累计质押股份2934.0万股，占其持股总数的78.79%，股东济南安富创业投资合伙企业已累计质押股份338.0万股，占其持股总数的53.65%。科源制药主营业务：化学原料药及其制剂产品的研发、生产和销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026013000035139.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301281"],"gpt_icon":0},{"id":"2604218422","title":"科源制药（301281）披露2025年限制性股票激励计划议案获股东会通过，1月19日股价上涨2.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2604218422","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604218422?lang=zh_cn&edition=full","pubTime":"2026-01-19 17:35","pubTimestamp":1768815317,"startTime":"0","endTime":"0","summary":"截至2026年1月19日收盘，科源制药报收于31.78元，较前一交易日上涨2.12%，最新总市值为34.41亿元。该股当日开盘31.0元，最高32.45元，最低30.94元，成交额达6521.78万元，换手率为2.98%。根据近日发布的公告，山东科源制药股份有限公司于2026年1月16日召开2026年第一次临时股东会，审议通过《关于公司<2025年限制性股票激励计划（草案）>及其摘要的议案》等多项议案。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011900023987.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301281","BK0239"],"gpt_icon":0},{"id":"2603252612","title":"科源制药（301281）披露召开2026年第一次临时股东会提示性公告，1月14日股价上涨1.44%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603252612","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603252612?lang=zh_cn&edition=full","pubTime":"2026-01-14 22:46","pubTimestamp":1768401974,"startTime":"0","endTime":"0","summary":"截至2026年1月14日收盘，科源制药报收于31.76元，较前一交易日上涨1.44%，最新总市值为34.39亿元。该股当日开盘31.47元，最高32.97元，最低31.12元，成交额达1.56亿元，换手率为7.05%。公司近日发布公告，将于2026年1月16日召开2026年第一次临时股东会，会议采取现场投票与网络投票相结合的方式。股权登记日为2026年1月12日。公司将对中小投资者的表决单独计票。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011400041673.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301281"],"gpt_icon":0},{"id":"2603651033","title":"科源制药：注射剂智能制造项目正稳步推进","url":"https://stock-news.laohu8.com/highlight/detail?id=2603651033","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603651033?lang=zh_cn&edition=full","pubTime":"2026-01-14 08:37","pubTimestamp":1768351027,"startTime":"0","endTime":"0","summary":"证券之星消息，科源制药(301281)01月13日在投资者关系平台上答复投资者关心的问题。投资者提问：请问公司的AI数智工厂去年9月底已落成，目前进展到哪一步了，是否已经投产，目前有无实质订单落地？科源制药回复：尊敬的投资者您好，公司注射剂智能制造项目正在按计划稳步推进中，目前正在办理药品生产许可事项，感谢您的关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011400006575.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301281"],"gpt_icon":0},{"id":"2603638040","title":"科源制药（301281）披露公司2025年限制性股票激励计划内幕信息知情人买卖公司股票情况的自查报告，1月13日股价上涨1.56%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603638040","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603638040?lang=zh_cn&edition=full","pubTime":"2026-01-13 22:45","pubTimestamp":1768315514,"startTime":"0","endTime":"0","summary":"截至2026年1月13日收盘，科源制药报收于31.31元，较前一交易日上涨1.56%，最新总市值为33.91亿元。公司近日发布公告，就2025年限制性股票激励计划内幕信息知情人买卖公司股票情况进行自查说明。公告显示，科源制药于2025年12月29日召开董事会，审议并通过了《关于公司<2025年限制性股票激励计划（草案）>及其摘要的议案》。经向中国证券登记结算有限责任公司深圳分公司查询，自查期间所有内幕信息知情人均无买卖公司股票的行为。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011300042631.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301281"],"gpt_icon":0},{"id":"2600060927","title":"每周股票复盘：科源制药（301281）推300万股限制性股票激励计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2600060927","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600060927?lang=zh_cn&edition=full","pubTime":"2026-01-03 03:44","pubTimestamp":1767383051,"startTime":"0","endTime":"0","summary":"截至2025年12月31日收盘，科源制药报收于29.3元，较上周的29.65元下跌1.18%。本周，科源制药12月29日盘中最高价报30.23元。本周关注点公司公告汇总：科源制药拟实施2025年限制性股票激励计划，授予总量300.00万股，占公司总股本的2.77%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010300002332.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301281","BK0239"],"gpt_icon":0},{"id":"2595784221","title":"科源制药(301281.SZ)拟推2025年限制性股票激励计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2595784221","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595784221?lang=zh_cn&edition=full","pubTime":"2025-12-29 19:12","pubTimestamp":1767006770,"startTime":"0","endTime":"0","summary":"智通财经APP讯，科源制药(301281.SZ)发布2025年限制性股票激励计划(草案)，拟向激励对象授予的限制性股票总量为300万股，约占本激励计划草案公告时公司股本总额的2.77%。其中，首次授予限制性股票240万股，预留60万股。授予价格为14.71元/股。此次激励计划有效期自限制性股票首次授予之日起至激励对象获授的限制性股票全部归属或作废失效之日止，最长不超过48个月。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1386655.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","301281"],"gpt_icon":0},{"id":"2590430643","title":"科源制药：在海南设有子公司林恒药业","url":"https://stock-news.laohu8.com/highlight/detail?id=2590430643","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590430643?lang=zh_cn&edition=full","pubTime":"2025-12-10 15:06","pubTimestamp":1765350386,"startTime":"0","endTime":"0","summary":"证券之星消息，科源制药(301281)12月10日在投资者关系平台上答复投资者关心的问题。投资者提问：请问贵司在海南省是否有子公司？是否在海南省有相关业务布局？科源制药回复：尊敬的投资者您好，公司在海南投资设有子公司海南林恒药业有限公司，主要业务为医药商业代理及配送服务，是公司在下游产业链的延伸。感谢您的关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121000018887.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301281","BK0239"],"gpt_icon":0},{"id":"2590318703","title":"科源制药：三高和心血管原料药均有布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2590318703","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590318703?lang=zh_cn&edition=full","pubTime":"2025-12-09 15:21","pubTimestamp":1765264882,"startTime":"0","endTime":"0","summary":"证券之星消息，科源制药(301281)12月09日在投资者关系平台上答复投资者关心的问题。投资者提问：请问公司在三高和心血管原料药是否有布局，未来是否有考虑保健品原料药？科源制药回复：尊敬的投资者您好，公司产品聚焦慢病领域，三高和心血管原料药均有布局，目前降糖类主要原料药为格列齐特和盐酸二甲双胍，心血管类主要原料药为单硝酸异山梨酯，目前公司暂未布局保健品原料药，感谢您的关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120900018308.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","301281"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1774837545605,"stockEarnings":[{"period":"1week","weight":-0.1992},{"period":"1month","weight":-0.0626},{"period":"3month","weight":0.3221},{"period":"6month","weight":0.1667},{"period":"1year","weight":0.2419},{"period":"ytd","weight":0.3379}],"compareEarnings":[{"period":"1week","weight":-0.011},{"period":"1month","weight":-0.0563},{"period":"3month","weight":-0.0126},{"period":"6month","weight":0.0224},{"period":"1year","weight":0.1601},{"period":"ytd","weight":-0.0139}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"山东科源制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"11085人(较上一季度减少11.26%)","perCapita":"6211股","listingDate":"2023-04-04","address":"山东省济南市商河县经济开发区科源街","registeredCapital":"10829万元","survey":" 山东科源制药股份有限公司的主营业务是化学原料药及其制剂产品的研发、生产和销售。公司的主要产品是化学原料药、化学药品制剂、中间体。","listedPrice":44.18},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"科源制药(301281)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供科源制药(301281)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"科源制药,301281,科源制药股票,科源制药股票老虎,科源制药股票老虎国际,科源制药行情,科源制药股票行情,科源制药股价,科源制药股市,科源制药股票价格,科源制药股票交易,科源制药股票购买,科源制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"科源制药(301281)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供科源制药(301281)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}